FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1604727671> ?p ?o ?g. }

• W1604727671 endingPage "685" @default.
• W1604727671 startingPage "679" @default.
• W1604727671 abstract "Background The pathogenesis of diabetic peripheral neuropathy remains uncertain and nonenzymatic glycoxidation is one of the contributing mechanisms. The aim of this study was to assess the respective relationship of diabetic peripheral neuropathy with glycoxidation, compared with other identified risk factors, in patients with type 2 diabetes. Methods We included 198 patients with type 2 diabetes and high risk for vascular complications. Circulating concentrations of three advanced glycation end products (carboxymethyllysine, methyl-glyoxal-hydroimidazolone-1, pentosidine) and of their soluble receptor (sRAGE) were measured. Peripheral neuropathy was assessed by the neuropathy disability score and by the monofilament test and defined as either an abnormal monofilament test and/or a neuropathy disability score ≥6. Multivariate regression analyses were performed adjusting for potential confounding factors for neuropathy: age, gender, diabetes duration, current smoking, systolic blood pressure, waist circumference, height, peripheral arterial occlusive disease, glycated haemoglobin, estimated glomerular filtration rate and lipid profile. Results Prevalence of peripheral neuropathy was 20.7%. sRAGE and carboxymethyllysine were independently and positively associated with the presence of peripheral neuropathy. No significant association was found between peripheral neuropathy and methyl-glyoxal-hydroimidazolone-1 or pentosidine. Waist circumference, height and peripheral arterial occlusive disease were independently associated with peripheral neuropathy. Conclusions Carboxymethyllysine and sRAGE were independently associated with peripheral neuropathy in patients with type 2 diabetes. Although the conclusions are limited by the absence of a healthy control population, this study confirms the relationship between advanced glycoxidation and diabetic peripheral neuropathy, independently of other risk factors. Copyright © 2014 John Wiley & Sons, Ltd." @default.
• W1604727671 created "2016-06-24" @default.
• W1604727671 creator A5001504751 @default.
• W1604727671 creator A5002639584 @default.
• W1604727671 creator A5019628589 @default.
• W1604727671 creator A5025877737 @default.
• W1604727671 creator A5060231570 @default.
• W1604727671 creator A5060274898 @default.
• W1604727671 creator A5067970712 @default.
• W1604727671 creator A5068258966 @default.
• W1604727671 date "2014-11-01" @default.
• W1604727671 modified "2023-10-17" @default.
• W1604727671 title "Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes" @default.
• W1604727671 cites W128364201 @default.
• W1604727671 cites W148758476 @default.
• W1604727671 cites W1511701404 @default.
• W1604727671 cites W1694482919 @default.
• W1604727671 cites W1892066952 @default.
• W1604727671 cites W1968596988 @default.
• W1604727671 cites W1972459018 @default.
• W1604727671 cites W1984637736 @default.
• W1604727671 cites W1985869922 @default.
• W1604727671 cites W1991120351 @default.
• W1604727671 cites W2012124401 @default.
• W1604727671 cites W2046632943 @default.
• W1604727671 cites W2059659922 @default.
• W1604727671 cites W2064506012 @default.
• W1604727671 cites W2073316984 @default.
• W1604727671 cites W2095408555 @default.
• W1604727671 cites W2103860004 @default.
• W1604727671 cites W2108762011 @default.
• W1604727671 cites W2115372776 @default.
• W1604727671 cites W2122567972 @default.
• W1604727671 cites W2128510213 @default.
• W1604727671 cites W2135932738 @default.
• W1604727671 cites W2148715056 @default.
• W1604727671 cites W2163577764 @default.
• W1604727671 cites W4240799972 @default.
• W1604727671 doi "https://doi.org/10.1002/dmrr.2529" @default.
• W1604727671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24449227" @default.
• W1604727671 hasPublicationYear "2014" @default.
• W1604727671 type Work @default.
• W1604727671 sameAs 1604727671 @default.
• W1604727671 citedByCount "41" @default.
• W1604727671 countsByYear W16047276712014 @default.
• W1604727671 countsByYear W16047276712015 @default.
• W1604727671 countsByYear W16047276712016 @default.
• W1604727671 countsByYear W16047276712017 @default.
• W1604727671 countsByYear W16047276712018 @default.
• W1604727671 countsByYear W16047276712019 @default.
• W1604727671 countsByYear W16047276712020 @default.
• W1604727671 countsByYear W16047276712021 @default.
• W1604727671 countsByYear W16047276712022 @default.
• W1604727671 countsByYear W16047276712023 @default.
• W1604727671 crossrefType "journal-article" @default.
• W1604727671 hasAuthorship W1604727671A5001504751 @default.
• W1604727671 hasAuthorship W1604727671A5002639584 @default.
• W1604727671 hasAuthorship W1604727671A5019628589 @default.
• W1604727671 hasAuthorship W1604727671A5025877737 @default.
• W1604727671 hasAuthorship W1604727671A5060231570 @default.
• W1604727671 hasAuthorship W1604727671A5060274898 @default.
• W1604727671 hasAuthorship W1604727671A5067970712 @default.
• W1604727671 hasAuthorship W1604727671A5068258966 @default.
• W1604727671 hasConcept C126322002 @default.
• W1604727671 hasConcept C134018914 @default.
• W1604727671 hasConcept C147990577 @default.
• W1604727671 hasConcept C2775892965 @default.
• W1604727671 hasConcept C2776997535 @default.
• W1604727671 hasConcept C2777180221 @default.
• W1604727671 hasConcept C2779178840 @default.
• W1604727671 hasConcept C2779901536 @default.
• W1604727671 hasConcept C2780758796 @default.
• W1604727671 hasConcept C46762472 @default.
• W1604727671 hasConcept C555293320 @default.
• W1604727671 hasConcept C71924100 @default.
• W1604727671 hasConcept C90924648 @default.
• W1604727671 hasConceptScore W1604727671C126322002 @default.
• W1604727671 hasConceptScore W1604727671C134018914 @default.
• W1604727671 hasConceptScore W1604727671C147990577 @default.
• W1604727671 hasConceptScore W1604727671C2775892965 @default.
• W1604727671 hasConceptScore W1604727671C2776997535 @default.
• W1604727671 hasConceptScore W1604727671C2777180221 @default.
• W1604727671 hasConceptScore W1604727671C2779178840 @default.
• W1604727671 hasConceptScore W1604727671C2779901536 @default.
• W1604727671 hasConceptScore W1604727671C2780758796 @default.
• W1604727671 hasConceptScore W1604727671C46762472 @default.
• W1604727671 hasConceptScore W1604727671C555293320 @default.
• W1604727671 hasConceptScore W1604727671C71924100 @default.
• W1604727671 hasConceptScore W1604727671C90924648 @default.
• W1604727671 hasFunder F4320323831 @default.
• W1604727671 hasIssue "8" @default.
• W1604727671 hasLocation W16047276711 @default.
• W1604727671 hasLocation W16047276712 @default.
• W1604727671 hasOpenAccess W1604727671 @default.
• W1604727671 hasPrimaryLocation W16047276711 @default.
• W1604727671 hasRelatedWork W1563922775 @default.
• W1604727671 hasRelatedWork W1604727671 @default.
• W1604727671 hasRelatedWork W1993428219 @default.

• next